Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551865 | 1.00 | CASR (0.62) | CASRLMNAKMT2AMEN1TDP1 | |
| SCHEMBL4073722 | 1.00 | CASR (0.62) | CASRLMNAKMT2AMEN1TDP1 | |
| SCHEMBL14469768 | 0.92 | CASR (0.58) | CASRLMNAKMT2AMEN1TDP1 | |
| Cadaverine Tartrate SCHEMBL5825857 | 0.90 | KMT2A (0.59) | CASRLMNAKMT2AMEN1TDP1 | |
| Cadaverine Tartrate SCHEMBL5825862 | 0.90 | KMT2A (0.59) | CASRLMNAKMT2AMEN1TDP1 | |
| Trifluoroacetic Acid SCHEMBL28937395 | 0.89 | CASR (0.61) | CASRLMNAKMT2AMEN1TDP1 | |
| Trifluoroacetic Acid SCHEMBL29551765 | 0.89 | CASR (0.61) | CASRLMNAKMT2AMEN1TDP1 | |
| SCHEMBL13868189 | 0.88 | CASR (0.73) | CASRLMNAKMT2AMEN1TDP1 | |
| SCHEMBL3921801 | 0.86 | CASR (0.67) | CASRLMNAKMT2AMEN1TDP1 | |
| SCHEMBL13868174 | 0.86 | CASR (0.78) | CASRLMNAKMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107759466-B | Splitting method of (+/-) -2- (3-benzoyl) -phenylpropionic acid | 浙江瑞博制药有限公司 | 2022-04-08 | — | — | CN | claimed |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | claimed |
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | claimed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | claimed |
| CN-116730993-A | Teranavir intermediate and preparation method of Teranavir | 浙江科技学院 | 2023-09-12 | — | — | CN | disclosed |
| CN-107759466-B | Splitting method of (+/-) -2- (3-benzoyl) -phenylpropionic acid | 浙江瑞博制药有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-2802554-B1 | PREPARATION OF OPTICALLY PURE ß-AMINO ACID TYPE ACTIVE PHARMACEUTICAL INGREDIENTS AND INTERMEDIATES THEREOF | LEK PHARMACEUTICALS (SI) | 2018-04-25 | — | — | EP | disclosed |
| CN-104159886-B | Preparation of optically pure beta-amino acid active pharmaceutical ingredients and intermediates thereof | 力奇制药公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-104159886-A | Preparation of optically pure beta-amino acid active pharmaceutical ingredients and intermediates thereof | LEK PHARMACEUTICALS | 2014-11-19 | — | — | CN | disclosed |
| EP-2615080-A1 | Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof | LEK Pharmaceuticals d.d. (SI) | 2013-07-17 | — | — | EP | disclosed |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | disclosed |
| EP-1778662-A1 | PHOTORACEMIZATION OF 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006011045-A1 | PHOTORACEMIZATION OF 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | ACKR3, KIT, C3AR1 | CASR 2647/4885LMNA 981/4885KMT2A 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.